Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Inclusion Criteria:

• Subject is currently enrolled in a pre-defined Novartis-sponsored study and isreceiving spartalizumab as single agent or in combination with other studytreatment,

• Subject is currently deriving clinical benefit from the study treatment, asdetermined by the investigator.

Other protocol defined inclusion criteria may apply

Exclusion Criteria:

• Subject has been permanently discontinued from spartalizumab in the parent protocolfor any reason other than enrollment in the Roll over Study

• Subject does not meet the criteria specified in the parent protocol criteria forcontinued study treatment.